SPRYARS Pharmaceuticals Inc

CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky PR Newswire NEW YORK, July 6, 2026 ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy failed...

Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched the value drop more than 23% in after-hours trading on June 24, 2026, after the Company disclosed that Neffy received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. Investors...

ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY) PR Newswire NEW YORK, June 29, 2026...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (ARS or the Company) (NASDAQ: SPRY) for violations of the securities laws.The investigation focuses on whether the Company issued false...

The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans.

Many patients will continue to face higher out-of-pocket costs or rely on the company’s cash-pay option without broader commercial coverage.

ARS Pharmaceuticals Q1 Earnings Call Highlights...

read more...